deferiprone
Selected indexed studies
- Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. (JAMA Neurol, 2025) [PMID:39495531]
- Deferiprone: New insight. (Ann N Y Acad Sci, 2005) [PMID:16339662]
- Deferiprone protects against photoreceptor degeneration by inhibiting parthanatos. (Cell Death Dis, 2025) [PMID:40389413]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. (2025) pubmed
- Deferiprone: New insight. (2005) pubmed
- Deferiprone protects against photoreceptor degeneration by inhibiting parthanatos. (2025) pubmed
- Deferiprone for the treatment of transfusional iron overload in thalassemia. (2017) pubmed
- Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. (2022) pubmed
- Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. (2023) pubmed
- Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis. (2024) pubmed
- The Role of Deferiprone in Iron Chelation. (2018) pubmed
- Oral deferiprone for iron chelation in people with thalassaemia. (2007) pubmed
- Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review. (2021) pubmed